A Randomized Double-Blind Evaluation of the Pharmacokinetics Safety and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection
J
Jean Molleston, MD
Primary Investigator
Enrolling By Invitation
100 years or below
All
Phase
N/A
2 Locations
Brief description of study
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of TAF against the Hepatitis B Virus in all of the enrolled adolescent subjects.
Detailed description of study
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of TAF against the Hepatitis B Virus in all of the enrolled adolescent subjects.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Chronic Hepatitis B Virus Infection, Riley
-
Age: 100 years or below
-
Gender: All
Updated on
05 Jun 2025.
Study ID: PGI-GILEAD-SUBBARAO-TAF, 1611090671
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
